Oncology and Radiotherapy

Beacon Hospital have been actively involved in Oncology research since 2009. This speciality has completed high quality, cancer research by means of clinical trials on the use of new techniques and treatments. Clinical trials allow additional access to oncology services, treatments and also for the contribution to the discovery of new techniques, that it is hoped, may benefit patients in the future.

All clinical trials carried out in Beacon Hospital adhere to strict international governance and regulations including the International Council for Harmonisation-Good Clinical Practice standards. A large proportion of clinical trials completed in Beacon Hospital are trials sponsored by Cancer Trials Ireland. The Oncology service also actively participates in a number of national and international clinical trials and continues to grow and expand. Further details on each trial can be accessed through the links provided below each clinical trial title.

Principal Investigators listed are Beacon Hospital Principal Investigators

Phase III IGRT & SBRT VS IGRT & Hypofractionated IMRT for Localised Intermediate Risk Prostrate Cancer

Stereotactic Body Radiation Therapy (SBRT) is a technique that provides radiation treatment to a patient within in a shorter time-frame when compared delivery of standard radiation therapy. The purpose of this study is to compare either positive or negative effects of using stereotactic body radiation therapy.

SBRT uses special equipment to position a participant and precisely deliver radiation to tumours in the body. Both the study and the usual radiation treatments use daily images to guide the radiation treatment to protect normal tissue. The study treatment (treatment over a shorter amount of time) may prevent the tumour from returning but it could also cause side effects. This study will allow researchers to know whether this different approach using SBRT is an improvement, comparable, or inferior to the usual approach.

The Principal Investigator on this study is Dr. Alina Mihai

ClinicalTrials.gov Identifier: NCT03367702

For more information on this trial click here: https://clinicaltrials.gov/ct2/show/NCT03151629

This study is supported by Cancer Trials Ireland: https://www.cancertrials.ie/

IRONMAN: International Registry for Men with Advanced Prostrate Cancer

Prostate cancer is a complex disease and there is an urgent need to identify the optimal treatment patterns and strategies for men with advanced prostate cancer. There are many treatment options available but no single study has evaluated all possible combinations of treatments with respect to: response to treatment, patient survival and patient quality of life. The goal of this study is to establish an international patient registry that will facilitate better understanding of how different treatment strategies are associated with survival and other health outcomes.

There is an evolving understanding of the biology underlying advanced prostate cancer including the identification of biomarkers that can predict response to treatment. This study will further add to our understanding of how this disease progresses and responds to treatment by identifying biomarkers using patient blood samples. Quality of life questionnaires and clinical data combined with the biomarker results will potentially aid clinicians to decide on the most optimum treatment strategies for future patients with advanced prostate cancer.

The Principal Investigator on this study is Prof Ray McDermott

Clinical Trials Gov Identifier: NCT03151629

For more information on this trial click here: https://clinicaltrials.gov/ct2/show/NCT03151629

This study is supported by Cancer Trials Ireland: https://www.cancertrials.ie/

Oligometastatic Disease: Phase III Randomised Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment for Oligometastatic (1-3 metastases) cancer SABR-COMET-3

The Principal Investigator on this study is Dr Alina Mihai

Clinical Trials Gov Identifier: NCT0386291

Prostate Cancer: CTRIAL-IE 15-46 Prostate Advances in Comparative Evidence (PACE) International Randomised Study of Prostatectomy vs Sterotactic Body Radiotherapy (SBRT) and Conventional Radiotherapy vs SBRT for Early Stage Organ-confined Prostate Cancer

The Principal Investigator on this study is Dr Alina Mihai

Clinical Trials Gov Identifier: NCT01584258

For more information on this trial please click the following link:

https://clinicaltrials.gov/ct2/show/NCT01584258?term=NCT01584258&draw=2&rank=1

Breast Cancer: ICORG 10-15 Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

The Principal Investigator on this study is Dr Jennifer Westrup

Clinical Trials Gov Identifier: NCT01840306

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT01840306?term=NCT01840306&draw=2&rank=1

Breast Cancer: ICORG 10-16 Study to determine alteration of hormone levels in premenopausal patients receiving adjuvant or neo-adjuvant chemotherapy for breast cancer

The Principal Investigator on this study is Dr Jennifer Westrup

Clinical Trials Gov Identifier: NCT01726322

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT01726322?term=NCT01726322&draw=2&rank=1

Colorectal Cancer: ICORG 12-27 Identification of plasma biomarkers in early detection of Colorectal Adenocarcinoma recurrence (C-RAC Plasma Biomarker Study)

The Principal Investigator on this study is Prof Ray McDermott

Clinical Trials Gov Identifier: NCT02050737

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT02050737?term=NCT02050737&draw=1&rank=1

Pancreatic Cancer: ICORG 12-31 Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma (PDAC Plasma Biomarker Study)

The Principal Investigator on this study is Prof Ray McDermott

Clinical Trials Gov Identifier: NCT02050997

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT02050997?term=NCT02050997&draw=2&rank=1

Prostate Cancer: ICORG 06-15 Proteomic analysis of the combined hormonal therapy and radiation therapy for localised prostate cancer

The Principal Investigator on this study is Prof John Armstrong

Clinical Trials Gov Identifier: NCT00955435

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT00955435?term=NCT00955435&draw=2&rank=1

Prostate Cancer: FE200486 CS39: A prospective observational safety study in patients with advanced Prostate Cancer treated with Firmagon ® (Degarelix) or a GnRH Agonist

The Principal Investigator on this study is Dr Alina Mihai

This is a study involving patients that are prescribed Firmagon as a first line treatment as part of their prostate cancer management and followed up during their routine standard of care

Prostate Cancer: ICORG 08-17 A prospective phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer

The Principal Investigator on this study is Prof John Armstrong and Dr Alina Mihai

Clinical Trials Gov Identifier: NCT00951535

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT00951535?term=NCT00951535&draw=2&rank=1

Prostate Cancer: ICORG 14-04 ”Irish Programme for Stratified Prostate Cancer Therapy iPROSPECT”

The Principal Investigator on this study is Prof Ray McDermott

This study is in relation to both the identification of predictive biomarkers for androgen deprivation therapy (ADT) treatment or ADT combined treatment response in metastatic prostate cancer (mPCa) and identification of predictive biomarker(s) for treatment response in metastatic castration resistant prostate cancer (mCRPC).

ICORG 14-06 Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET)

The Principal Investigator on this study is Prof Ray McDermott

Clinical Trials Gov Identifier: NCT02446405

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT02446405?term=NCT02446405&draw=2&rank=1

CTRIAL-IE 14-07 Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised Prostate Cancer (ENZARAD)

The Principal Investigator on this study is Dr Alina Mihai

Clinical Trials Gov Identifier: NCT02446444

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT02446444?term=NCT02446444&draw=2&rank=1

ICORG 15-43 Clinical Research Questionnaire of Oncology Patients – A Nationwide Survey

The Principal Investigator on this study is Dr Alina Mihai

This is a 10 minute anonymous questionnaire that oncology patients can complete that examines what cancer patients know about cancer research and what drives their decision about taking part in cancer research.

Lung Cancer: CTRIAL-IE 15-47 INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer

The Principal Investigator on this study is Prof. John Armstrong

Oligometastatic Disease: ICORG 15-05 (UPCI 10-028) Radiosurgery for Patients with Recurrent Oligometastatic Disease

The Principal Investigator on this study is Dr Alina Mihai

Clinical Trials Gov Identifier: NCT01345552

For more information on this trial please click the following link: https://clinicaltrials.gov/ct2/show/NCT01345552?term=NCT01345552&draw=2&rank=1